Helping Adults With Type 2 Diabetes Use Their Health Data for Healthy Diabetes Self-Management

Last updated: May 4, 2026
Sponsor: Ann-Marie Rosland
Overall Status: Active - Enrolling

Phase

N/A

Condition

Diabetes And Hypertension

Diabetes Prevention

Diabetes Mellitus, Type 2

Treatment

Continuous Glucose Monitor (CGM)

Activity Monitor

MPowerHub

Clinical Study ID

NCT06848361
STUDY23080053
1R01DK136788-01A1
  • Ages 25-75
  • All Genders

Study Summary

Day-to-day self-management by adults with type 2 diabetes, including glucose monitoring, taking medications, and healthy habits, is essential to avoid diabetes complications, yet, despite the rapidly expanding availability of wearable glucose and activity monitors, successful self-management remains challenging for many. This research aims to develop and test an approach to help adults use their personal diabetes information from wearable devices to achieve and sustain health diabetes self-management, which will reduce diabetes complications, and improve health and quality of life for people with type 2 diabetes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Received outpatient care in the participating health system in the last 12 months

  • Has a diagnosis of type 2 diabetes mellitus (ICD10 codes E08.xx, E09.xx, E11.xx,E13.xx,O24.1x , O24.3x, O24.8x, O24.9x)

  • Last Hemoglobin A1c (HbA1c) value obtained in the last 6 months was ≥7.5%

  • Currently prescribed at least one non-insulin diabetes medication

  • Able to provide informed consent

  • Able to interact with a simple smartphone application

  • Owns or has access to a smartphone that is able to access an internet website

  • Did not participate a prior study related to this protocol

Exclusion

Exclusion Criteria:

  • Originally was diagnosed with type 2 diabetes before the age of 21 years

  • Has a diagnosis of type 1 diabetes mellitus

  • Has a diagnosis of gestational diabetes without any other diabetes diagnoses

  • Is currently prescribed insulin

  • Currently is using a CGM device

  • Has a diagnosis (active or prior) of schizophrenia or other psychotic/delusionaldisorder

  • Has a life-limiting severe illness (e.g., chronic obstructive pulmonary diseaserequiring oxygen)

  • Is pregnant or planning to become pregnant within the next 6 months

  • Has other concerns that may interfere significantly with their ability toparticipate in the intervention (ongoing health issues, personal events, etc.)

  • Currently is enrolled in another diabetes management intervention study

Study Design

Total Participants: 80
Treatment Group(s): 3
Primary Treatment: Continuous Glucose Monitor (CGM)
Phase:
Study Start date:
April 28, 2025
Estimated Completion Date:
December 31, 2026

Study Description

MPowerHub trial protocol feasibility will be assessed by randomizing 80 adults with type 2 diabetes and glycemic levels above clinical goals to MPowerHub (MPowerHub platform + continuous glucose monitoring & activity monitoring), continuous glucose monitor alone, or activity monitor alone for four months. Mixed quantitative and qualitative assessments will examine recruitment, engagement, and retention metrics and feedback. Finally, changes in self-management behaviors (measured using semi-structured interview) and clinic glycemic levels (obtained from participants' electronic health record or finger-stick by study research staff) from pre- to post-monitoring will be compared between arms.

Connect with a study center

  • University of Pittsburgh

    Pittsburgh, Pennsylvania 15213
    United States

    Site Not Available

  • University of Pittsburgh

    Pittsburgh 5206379, Pennsylvania 6254927 15213
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.